Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novartis Will Acquire A Nektar Business
by Michael McCoy
October 27, 2008
| A version of this story appeared in
Volume 86, Issue 43
Novartis has agreed to acquire Nektar Therapeutics' pulmonary drug delivery business for $115 million in cash. The deal includes a facility in San Carlos, Calif., which employs about 140 people. Novartis says it will use Nektar technology to advance the development of drugs for diseases such as asthma and cystic fibrosis. Nektar's technology was used in Pfizer's Exubera inhaled insulin until Pfizer pulled the drug from the market last year. Nektar says it will focus on drugs that use its PEGylation and conjugate chemistry technologies.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter